Business / Finance

RSS

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.

31 Mar 2014

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health product, Probi Mage®. The Product will be launched under Probi's brand in South Korea in the second quarter of 2014.

31 Mar 2014

Panasonic and KKR complete share purchase agreement

Panasonic Corporation ("Panasonic") and KKR, a leading global investment firm, today announced the completion of a share purchase agreement and a shareholders' agreement under which Panasonic and KKR have become joint partners of Panasonic Healthcare Co., Ltd. ("Panasonic Healthcare").

From PHC Europe B.V. 31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN® (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan.

31 Mar 2014

Aeterna Zentaris declares effectiveness of Form F-3 shelf registration statement filed with SEC

Aeterna Zentaris Inc. (the "Company") today announced that its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission (the "SEC") has been declared effective by the SEC.

29 Mar 2014

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

29 Mar 2014

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three months and full year ended December 31, 2013.

29 Mar 2014

Nautilus offers second-look financing to Genesis Credit

Nautilus, Inc., a leader in innovative home fitness equipment, is pleased to announce a partnership with Genesis Financial Solutions to offer Genesis Credit second-look financing.

29 Mar 2014

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.

29 Mar 2014

RegeneRx obtains $1.35M payment pursuant to product license, securities purchase deal with G-treeBNT

RegeneRx Biopharmaceuticals, Inc. today announced that it received the initial $1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co., Ltd (formerly Digital Aria Co., Ltd.), headquartered in Gyeonggi-do, Korea, for G-treeBNT to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S.

29 Mar 2014

Nordion enters into definitive agreement to be acquired by Sterigenics

Nordion Inc., a leading provider of products and services to the global health science market, announced that it has entered into a definitive agreement (the "Arrangement Agreement") to be acquired by Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA.

29 Mar 2014

American Bio Medica's net sales decrease 7.3% in fourth quarter 2013

American Bio Medica Corporation today announced financial results for the fourth quarter and year ended December 31, 2013.

From Medica Corporation 29 Mar 2014

Massachusetts Life Sciences Center provides $1.65M in capital grant to North Shore InnoVentures

North Shore InnoVentures, one of New England's leading technology incubators and business accelerators, announced today that it has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center.

From Evident Corporation - Life Sciences 28 Mar 2014

Cardiome signs deal with VIANEX to commercialize and distribute BRINAVESS in Greece

Cardiome Pharma Corp. today announced that Cardiome International A.G., a subsidiary of Cardiome Pharma Corp., has entered into an agreement with VIANEX, S.A., headquartered in Erythrea, Greece, for the commercialization and distribution of BRINAVESS™ (vernakalant IV) in Greece.

28 Mar 2014

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.

28 Mar 2014

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012.

28 Mar 2014

Nanosonics partners with Miele Professional to distribute trophon EPR in Germany

Nanosonics Limited is pleased to announce it has entered into a strategic partnership with Miele Professional for the distribution of trophon EPR in Germany.

28 Mar 2014

Everyday Health prices initial public offering of common stock

Everyday Health, Inc. today announced the pricing of its initial public offering of 7,150,000 shares of its common stock at a price to the public of $14.00 per share.

28 Mar 2014

Endo Health Solutions to commence exchange offers on all outstanding unsecured Senior Notes

Endo International plc announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion (collectively, the "Existing EHSI Notes"), for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes"), respectively, issued by Endo Finance LLC ("Endo Finance") and Endo Finco Inc.

28 Mar 2014

Business / Finance

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Panasonic and KKR complete share purchase agreement

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Aeterna Zentaris declares effectiveness of Form F-3 shelf registration statement filed with SEC

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nautilus offers second-look financing to Genesis Credit

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

RegeneRx obtains $1.35M payment pursuant to product license, securities purchase deal with G-treeBNT

Nordion enters into definitive agreement to be acquired by Sterigenics

American Bio Medica's net sales decrease 7.3% in fourth quarter 2013

Massachusetts Life Sciences Center provides $1.65M in capital grant to North Shore InnoVentures

Cardiome signs deal with VIANEX to commercialize and distribute BRINAVESS in Greece

ADMA Biologics reports consolidated net loss of $15.5M in 2013

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

Nanosonics partners with Miele Professional to distribute trophon EPR in Germany

Everyday Health prices initial public offering of common stock

Endo Health Solutions to commence exchange offers on all outstanding unsecured Senior Notes

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News